Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent.
SILVER SPRING, Md., Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS).
NEW YORK, Dec. 22 /PRNewswire/ -- 2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions.
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp.
Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange. MILWAUKEE, April 29 /PRNewswire/ -- Researchers at Aurora St.
Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...
Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug. MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
Acorda Therapeutics, Inc.
- An imitative word; an onomatopoetic word.